SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, fully-human
immunoglobulin (hIgG) antibodies, also known as fully-human
polyclonal antibodies, without the need for human donors, today
announced the appointment of Erick Lucera, CFA, a veteran of the
biotechnology and medical device industry, with over thirty years
of financial, operational and investment experience, to SAB’s Board
of Directors, effective April 4, 2023.
Most recently, Mr. Lucera served as chief
financial officer for AVEO Oncology, a commercial stage
oncology-focused biopharmaceutical company, from January 2020 until
February 2023. Subsequent to the close of AVEO’s
acquisition by LG Chem, Ltd., he advised AVEO’s management team
through the transition.
“I am both excited and pleased to welcome Erick
to SAB’s Board of Directors,” said Samuel J. Reich, Executive
Chairman of SAB. “As SAB continues to advance its programs to and
through important milestones, I believe that Erick’s successful
track record, and wealth of experience in corporate finance, will
prove to be of great value to SAB. We are all looking forward to
working with him.”
Prior to his time at AVEO Oncology, Mr. Lucera
held chief financial officer and other senior roles at several
biotechnology and medical device companies. He was previously chief
financial officer of Valeritas, a publicly traded commercial-stage
medical technology company focused on developing solutions for
people with diabetes, where he led the company through multiple
successful public offerings. Prior to Valeritas, Mr. Lucera served
as chief financial officer, treasurer, and secretary of Viventia
Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a
biotechnology company focused on developing targeted protein
therapeutics for the treatment of cancer. He also previously served
as vice president, corporate development at Aratana Therapeutics, a
veterinary biopharmaceutical company, where he helped grow the
company’s product pipeline through a series of acquisitions and
in-licensing transactions financed through five public and private
offerings of nearly $250 million.
“Throughout my career, I’ve gravitated toward
innovative life science companies that are working to address
therapeutic areas with high unmet medical needs,” said Erick
Lucera, CFA. “With its novel drug development platform and focus on
immune and autoimmune disorders, SAB’s value proposition is unique
and exciting. I am honored to join the Board of Directors of a
cutting-edge company focused on critical disease states, such as C.
difficile and type 1 diabetes.”
Early in his career, Mr. Lucera spent more than
15 years covering healthcare and the life sciences in investment
management as a healthcare analyst at Eaton Vance, the portfolio
manager of the Triathalon Life Sciences Fund at Intrepid Capital
and as head of the healthcare research team at Independence
Investments. He began his career as a staff auditor and accountant
at Price Waterhouse & Co. (now PwC).
Mr. Lucera holds a Certification in Public
Health (CPH) from Harvard University, as well as an MS from Boston
College and an MBA from Indiana University Bloomington. He earned
his BS in accounting from the University of Delaware. Additionally,
Mr. Lucera currently holds a CFA designation. He previously held
CMA and CPA designations, now expired.
About SAB Biotherapeutics,
Inc.
SAB Biotherapeutics, Inc. (SAB) We are a
clinical-stage biopharmaceutical company focused on the development
of powerful and proprietary immunotherapeutic polyclonal human
antibodies to treat and prevent infectious diseases and immune and
autoimmune disorders. Our development programs include infectious
diseases resulting from outbreaks and pandemics, as well as
immunological, gastroenterological, and respiratory diseases that
have significant mortality and health impacts on immune compromised
patients. SAB has applied advanced genetic engineering and antibody
science to develop Transchromosomic (Tc) Bovine™. Our versatile
DiversitAb™ platform is applicable to a wide range of serious unmet
needs in human diseases. It produces natural, specifically
targeted, high-potency, fully-human polyclonal immunotherapies
without the need for human donors. SAB currently has multiple drug
development programs underway and collaborations with the US
government and global pharmaceutical companies. For more
information on SAB, visit: https://www.SAb.bio/ and follow SAB on
Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally are
accompanied by words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect,” “should,” “would,”
“plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook”
and similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, including the positive impact
of new members of our Board of Directors, the development and
efficacy of our influenza program, C. diff. program, type 1
diabetes program, and other discovery programs, the likelihood that
a patent will issue from any patent application, the results,
including timing, of the development of SAB-176, SAB-185, SAB-142
and SAB-195 (including any IND filing or proposed clinical trials),
financial projections and future financial and operating results
(including estimated cost savings and cash runway), the outcome of
and potential future government and other third-party
collaborations or funded programs (including negotiations with the
DoD).
These statements are based on the current
expectations of SAB and are not predictions of actual performance,
and are not intended to serve as, and must not be relied on, by any
investor as a guarantee, prediction, definitive statement, or an
assurance, of fact or probability. These statements are only
current predictions or expectations, and are subject to known and
unknown risks, uncertainties and other factors which may be beyond
our control. Actual events and circumstances are difficult or
impossible to predict, and these risks and uncertainties may cause
our or our industry’s results, performance, or achievements to be
materially different from those anticipated by these
forward-looking statements. A further description of risks and
uncertainties can be found in the sections captioned “Risk Factors”
in our most recent annual report on Form 10-K, subsequent quarterly
reports on Form 10-Q, and other filings with or submissions to, the
U.S. Securities and Exchange Commission, which are available at
https://www.sec.gov/. Except as otherwise required by law, SAB
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events,
or circumstances or otherwise.
CONTACTS
Investor
Relations:SABIR@westwicke.com
Media Relations:SABPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Nov 2024 to Dec 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Dec 2023 to Dec 2024